Print
Advertisement
The FDA ODAC voted in favor of the use of MRD-negativity as an intermediate endpoint for accelerated approval in MM trials.
Dr. Vose discusses how she became a hematologist, how she nurtures her artistic side outside of work, and more.
Dr. Maddocks hopes that current trials will help us “spring forward” into a chemotherapy-free approach to treating MCL.
The conference has a lot of great sessions, including an untraditional keynote speaker, Dr. Hastings said.
Dr. Harrison discusses her current clinical research, building community with MPN Voice, and her journey into hematology.
A drug approval specific to CMML would catalyze a surge of interest in the hematology-oncology community.
Advertisement
Denileukin diftitox is an IL-2-based immunotherapy for patients with relapsed or refractory CTCL.
The CAR-T therapy was approved based on response rate and duration of response data from the TRANSCEND CLL 004 trial.
S. Vincent Rajkumar, MD, a myeloma clinician and researcher, currently serves as a Professor of Medicine at the Mayo Clinic.
The newly elected fellows will be formally recognized during the AACR Annual Meeting 2024 Opening Ceremony on April 7.
The award grants $100,000 to a postdoctoral or early-career oncology researcher from a racial/ethnic minority group.
UM171 promotes degradation of the CoREST1 complex and reduces levels of chromatin-bound MYC.
Most patients in the lower-dose group achieved complete remission or complete remission with partial hematologic recovery.
Adding daratumumab and hyaluronidase-fihj to lenalidomide, bortezomib and dexamethasone reduced the risk of progression.
Selinexor is an oral inhibitor for the treatment of relapsed or refractory multiple myeloma.
Dr. Pui, of St. Jude Children’s Research Hospital, discusses his lifelong commitment to being a pediatric oncologist.
CanScan uses low-depth whole-genome sequencing to detect early cancer signals with 99% specificity.
In a clinical trial, relma-cel demonstrated a three-month ORR of 81.36% in patients with relapsed or refractory MCL.
Researchers are working to define and validate the ways in which mass spectrometry can aid in MM diagnosis and monitoring.
This manufacturing process change results in a shorter manufacturing time for axi-cel from 16 days to 14 days.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.